The Pharmacology of CP‐154,526, a Non‐Peptide Antagonist of the CRH1 Receptor: A Review
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Since CRH has been shown to mediate stress‐induced physiological and behavioral changes, it has been hypothesized that CRH receptor antagonists may have therapeutic potential in disorders that involve excessive CRH activity. CP‐154,526 and its close analog antalarmin are potent, brain‐penetrable, selective nonpeptide CRH1 receptor antagonists that were discovered in an effort to develop compounds with efficacy in CNS disorders precipitated by stress. Since its discovery many investigators have used CP‐154,526 as a tool to study the pharmacology of CRH and its receptors and to evaluate its therapeutic potential in a variety of CNS and peripheral disorders. Systemically‐administered CP‐154,526 has been demonstrated to antagonize CRH‐ and stress‐induced neuroendocrine, neurochemical, electrophysiological, and behavioral effects. These findings support the hypothesis that CRH1 receptor antagonists may have therapeutic utility in a number of neuropsychiatric disorders. CP‐154,526, as well as other CRH1 receptor antagonists that have since been discovered, have also shown activity in several preclinical models of anxiety, depression, and substance abuse, while having little effect on locomotor activity and motor function. Although these effects are on occasion inconsistent among different laboratories, clinical evaluation of CRH 1 antagonists appears justified on the basis of these and clinical data implicating the involvement of CRH in several CNS disorders. The effects of CRH 1 antagonists on cognition, neurodegeneration, inflammation, and the gastrointestinal system have not been as extensively characterized and additional studies will be necessary to evaluate their therapeutic potential in these areas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vale, W., Spiess, J., Rivier, C., & Rivier, J. (1981) · Science · doi:10.1126/science.6267699 · Cited by 3,965
Nemeroff, C. B., Widerlöv, E., Bissette, G., Walléus, H., Karlsson, I., Eklund, K., Kilts, C. D., Loosen, P. T., & Vale, W. (1984) · Science · doi:10.1126/science.6334362 · Cited by 1,485 · cited 2×
“In depressed patients, several studies have reported elevated levels of CRH in cerebrospinal fluid (CSF), which then return to normal after successful therapy with antidepressant drugs or electroconvulsive shock (ECS) (2,137,139).”
BackgroundDunn, A. J., & Berridge, C. W. (1990) · Brain Research Reviews · doi:10.1016/0165-0173(90)90012-d · Cited by 1,352
Lewis, K., Li, C., Perrin, M. H., Blount, A., Kunitake, K., Donaldson, C., Vaughan, J., Reyes, T. M., Gulyas, J., Fischer, W., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.121165198 · Cited by 925 · cited 3×
“Schmidt, unpublished data), UCN has high affinity for both CRH1 and CRH2 receptors, and UCN II and UCN III have high affinity for CRH2 receptors (79,105,153).”
BackgroundTimpl, P., Spanagel, R., Sillaber, I., Kresse, A., Reul, J. M. H. M., Stalla, G. K., Blanquet, V., Steckler, T., Holsboer, F., & Wurst, W. (1998) · Nature Genetics · doi:10.1038/520 · Cited by 919
Reyes, T. M., Lewis, K., Perrin, M. H., Kunitake, K. S., Vaughan, J., Arias, C. A., Hogenesch, J. B., Gulyas, J., Rivier, J., Vale, W. W., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051626398 · Cited by 887 · cited 3×
“Schmidt, unpublished data), UCN has high affinity for both CRH1 and CRH2 receptors, and UCN II and UCN III have high affinity for CRH2 receptors (79,105,153).”
BackgroundHolsboer, F. (1999) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(98)90056-5 · Cited by 654
Pich, E., Lorang, M., Yeganeh, M., Rodriguez de Fonseca, F., Raber, J., Koob, G., & Weiss, F. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-08-05439.1995 · Cited by 565 · cited 1×
“For example, increased CRH release has been demonstrated during withdrawal from ethanol and cannabinoids (130,156) and intra-amygdaloid infusion of ah-CRH reversed the anxiogenic-like effects of ethanol withdrawal in an EPM test (152).”
BackgroundChang, C.-P., Pearse, R. V., O'Connell, S., & Rosenfeld, M. G. (1993) · Neuron · doi:10.1016/0896-6273(93)90230-o · Cited by 537
Activation of Corticotropin-Releasing Factor in the Limbic System During Cannabinoid Withdrawal
Rodrı́guez de Fonseca, F., Carrera, M. R. A., Navarro, M., Koob, G. F., & Weiss, F. (1997) · Science · doi:10.1126/science.276.5321.2050 · Cited by 499 · cited 2×
“CRH has also been reported to be involved in the anxiogenic and aversive symptoms of withdrawal from several drugs of abuse, including alcohol (129), opiates (68), cannabinoids (156), and cocaine (162).”
Background
Cited by
Millan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
(2005) · PubMed · Cited by 470
Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder
Kato, M., & Serretti, A. (2010) · Molecular Psychiatry · doi:10.1038/mp.2008.116 · Cited by 450
Hippocampal changes associated with early-life adversity and vulnerability to depression
Rao, U., Chen, L.-A., Bidesi, A. S., Shad, M. U., Thomas, M. A., & Hammen, C. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.10.017 · Cited by 383
The Flinders Sensitive Line rat: A selectively bred putative animal model of depression
Overstreet, D. H., Friedman, E., Mathé, A. A., & Yadid, G. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.03.015 · Cited by 380
Metadata
- Authors
- Seymour, P. A., Schmidt, A. W., & Schulz, D. W.
- Venue
- CNS Drug Reviews
- Publisher
- Wiley
- Published
- 2003-03
- Volume
- 9
- Issue
- 1
- Pages
- 57-96
- ISSN
- 1080-563X (ISSN-L)
- 1527-3458
- OpenAlex
- W2045417336
- Cited by
- 112
- References
- 22
- FWCI
- 4.33
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Pharmacology of CP‐154,526, a Non‐Peptide Antagonist of the CRH1 Receptor: A Review. https://app.cochat.ai/papers/10.1111/j.1527-3458.2003.tb00244.x
- The paper
- Seymour, P. A., Schmidt, A. W., & Schulz, D. W. (2003). The Pharmacology of CP‐154,526, a Non‐Peptide Antagonist of the CRH1 Receptor: A Review. CNS Drug Reviews. https://doi.org/10.1111/j.1527-3458.2003.tb00244.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.